illumicell AI

AI-powered platform for cellular data analysis, starting with male fertility diagnostics at the point of care.

Website: https://www.illumicell.ai

Cover Block

Metric Value
Company Name illumicell AI
Tagline AI-powered platform for cellular data analysis, starting with male fertility diagnostics at the point of care.
Headquarters Allston, Massachusetts
Founded 2023
Stage Pre-Seed
Business Model B2B
Industry Healthtech
Technology AI / Machine Learning
Geography Global / Remote-First
Growth Profile Venture Scale
Founding Team Co-Founders (2)
Funding Label Pre-seed (total disclosed ~$2,340,000)

Links

The Short Version

illumicell AI is a pre-seed stage healthtech company applying proprietary AI and microscopy to cellular diagnostics, with an initial wedge into the male fertility market where it claims to deliver lab-grade results at the point of care. The company's thesis rests on decentralizing a traditionally lab-bound diagnostic process. The founding team coalesced around a prior collaboration in telemedicine diagnostics, bringing together backgrounds in public health, biomedical sciences, and engineering [Pulse 2.0].

The core product is an AI-powered imaging platform that analyzes sperm samples using a Digital Inline Holographic Microscope (DIHM), a method the company states achieves 98% accuracy while being 50 times faster and 20 times cheaper than conventional analysis [CB Insights]. The go-to-market strategy is B2B, targeting integration into doctor's offices rather than specialized fertility clinics to enable immediate, in-clinic diagnostics.

To date, the company has raised approximately $2.3 million in pre-seed capital from a consortium of health-focused investors and accelerators, including KOFA Healthcare and Techstars Berlin [CB Insights]. The next 12-18 months will be critical for demonstrating commercial traction, securing regulatory pathways for its diagnostic claims, and transitioning from technical validation to initial customer deployments [Pulse 2.0].

Data Accuracy: YELLOW -- Core company description and funding amount are corroborated by multiple sources; specific performance claims are sourced to company interviews.

The Company in Brief

Illumicell AI was founded in 2023 as a venture to apply machine learning to cellular diagnostics, with its initial commercial focus on male fertility [Crunchbase]. The company is headquartered in Allston, Massachusetts. The founding narrative traces its origins to a prior telemedicine-enabled COVID-19 testing company called Testasy, which co-founder Jeyla Sadikova co-founded in 2021; the collaboration with co-founder Michel Bielecki from that venture led to the formation of illumicell AI [Pulse 2.0].

Key operational milestones are concentrated in its early funding and accelerator participation. The company was accepted into the Techstars Berlin Accelerator program in 2023 [LinkedIn]. In October 2023, illumicell AI closed a $2 million pre-seed financing round led by KOFA Healthcare [Med-Tech World]. The company also lists participation in the MassChallenge U.S. accelerator [CB Insights]. Public records show a subsequent capital infusion, with a pre-seed round of $2 million reported in April 2025.

Data Accuracy: YELLOW -- Founding year and headquarters confirmed by Crunchbase and a secondary source. Funding round amounts and dates are reported by multiple outlets, but investor details for the 2025 round are incomplete.

What They Have Built

The company’s initial product is a diagnostic platform for male fertility, using a proprietary hardware and software system to analyze sperm samples. The core proposition is to move this analysis from specialized labs to the point of care. According to co-founder Jeyla Sadikova, the system can deliver results with 98% accuracy, 50 times faster, and at 20 times lower cost than conventional laboratory methods [Pulse 2.0].

The technology combines a Digital Inline Holographic Microscope (DIHM) to capture cellular data, which is then processed by machine learning models to evaluate key sperm parameters like motility and morphology [Harvard Innovation Labs]. The company has published early validation data, reporting that its AI-enhanced device showed a significantly higher mean normal sperm morphology result (4.62%) compared to conventional microscopy (3.07%) in a study [Pulse 2.0].

Data Accuracy: YELLOW -- Performance claims are sourced from founder interviews and an early study; independent clinical validation and detailed product specifications are not yet publicly available from third parties.

Market Size and Demand

The market for accessible, data-driven fertility diagnostics is expanding. Illumicell AI's initial focus on male fertility testing enters a segment where the standard of care is often manual, lab-dependent, and perceived as a barrier to entry for broader patient screening.

Metric Value
Global Fertility Services Market (2022) $41.2B
Global Semen Analysis Market (2023) $1.3B

Demand is underpinned by declining male fertility rates, as documented in multiple epidemiological studies [Human Reproduction Update, 2017]. Concurrently, societal destigmatization of fertility issues and the growth of the direct-to-consumer health testing market have created a more receptive environment for novel diagnostic tools. Regulatory pathways, particularly FDA clearance for a Class II medical device, represent a significant macro force that will dictate the speed and scope of commercial deployment in the United States.

Data Accuracy: YELLOW -- Market sizing figures are cited from third-party analyst reports, but specific TAM/SAM for the company's precise product category is not publicly detailed.

Who Else Is Fighting for This

Illumicell AI's competitive position is defined by its attempt to shift male fertility diagnostics from centralized labs to the point of care, a wedge that pits it against both entrenched laboratory services and a newer wave of direct-to-consumer testing kits.

The competitive map in male fertility diagnostics is segmented by testing location and customer type. Incumbent laboratory service providers include large national networks like LabCorp and Quest Diagnostics, as well as specialized andrology labs. Direct-to-consumer (DTC) challengers compete on convenience and privacy but often trade off clinical-grade accuracy. Illumicell AI's proposed platform sits between these segments, aiming to offer lab-comparable accuracy at the physician's office.

Illumicell's claimed edge rests on its proprietary technology stack, specifically the combination of a Digital Inline Holographic Microscope (DIHM) and AI algorithms [illumicell AI]. The company's most significant exposure is its lack of commercial footprint and distribution. It has no publicly disclosed partnerships with clinic networks, hospital systems, or medical device distributors.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated market wedge and standard industry structure; no direct competitor names are publicly cited in company materials or coverage.

Opportunity

If illumicell AI's performance claims hold and its point-of-care model gains regulatory and commercial acceptance, the company could capture a significant portion of the global male fertility diagnostics market by displacing legacy lab workflows.

Scenario What happens Catalyst Why it's plausible
Clinic-First Standardization The AI device becomes the default semen analyzer in U.S. urology and fertility clinics. FDA 510(k) clearance for the device as a Class II medical device. The team's academic collaboration and published data suggest a pathway to regulatory submission [Pulse 2.0].
Platform Expansion into Female Fertility The underlying DIHM and AI analysis platform is adapted to analyze other cellular samples. A strategic partnership with a large women's health network or diagnostic company. The company's founding technology is described as a platform for "cellular data in fluid" [CB Insights].
Direct-to-Consumer & Telehealth Integration The device is deployed for at-home sample collection. Partnership with a major digital fertility clinic or men's health telehealth provider. Company materials mention enabling "accurate at-home fertility assessments" [Harvard Innovation Labs].

Data Accuracy: YELLOW -- The core market opportunity is inferred from the broader diagnostic sector; specific growth catalysts and the compounding flywheel are based on company statements and early research.

Sources

Articles about illumicell AI

Related companies

Topics

View on Startuply.vc